AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$CHE

Chemed Corp (CHE) Q3 2026 Earnings Call Highlights: VITAS Strength Drives 28% EPS Growth

Chemed Corp (CHE) reported Q3 2026 earnings with VITAS driving 28% EPS growth. Roto-Rooter saw a 2.5% EBITDA decline due to higher marketing and fuel costs. VITAS faces regulatory audits, reviewing $12-$14M in revenue. Chemed anticipates continued cost headwinds in Q4. Management discussed hiring, acquisitions, and lead generation strategies.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Chemed Corp (CHE) Q3 2026 Earnings Call Highlights: VITAS Strength Drives 28% EPS Growth — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$CHEBullishHigh
01

Why it matters

The beat and guidance may attract buying interest, but investors will monitor cost trends and integration of new franchises.

02

Market read

Earnings beat and guidance update are primary news for CHE, likely influencing its price in after‑hours trading.

03

What to watch

Potential regulatory audits at VITAS and integration risk of franchise acquisitions may delay margin recovery.

Relevance 7/10Novelty 8/10Timing: after-hours today

Background

Chemed Corp's Q3 earnings call provided detailed segment performance, cost headwinds, and updated full‑year guidance.

Company-level read

Ticker impact

$CHEBullishHigh confidence
Context

Chemed Corp reported Q3 2026 EPS beat and raised guidance, noting 28% EPS growth and cost headwinds.

Expected impact

likely modest upside as market prices in the EPS beat and guidance near the top end of range

Evidence & confidence

The fresh earnings numbers and guidance are primary disclosures; investors will reassess valuation, but ongoing cost pressures temper enthusiasm.

Market effects

Sector

Highlights cost pressures in the home services and hospice sectors, which may affect peers with similar margin structures.

Regional

U.S. healthcare and service‑industry stocks could see modest re‑rating based on Chemed's guidance.

Global

Limited to U.S. markets; no direct global macro impact.

Counterpoint

What could challenge this read

Margin compression could outweigh the earnings beat, prompting a short‑term pullback.

Key entities

  • Company
    Chemed Corp

    Parent company of VITAS Healthcare and Roto‑Rooter.

Read at source← All news

StoryChemed reports Q3 2026 earnings with double‑digit revenue growth and $62.5 M California franchise acquisition

Also covered by

4 outlets

Related articles

$CHEMedAI 9/10

Chemed 3Q 2026: Revenue $690.9M, EPS $5.45— 10-Q Summary

Chemed reported Q3 2026 revenue of $690.9M, up 10.6% YoY, with net income rising 11.5% to $71.6M and EPS increasing 22.2% to $5.45. Growth in VITAS and Roto-Rooter segments drove results, while higher fuel costs pressured margins. The company acquired RotoCo and other franchises, expanding its territories.

tradingview.com
$CHEMed

What Chemed (CHE) Said on Its Q3 Earnings Call

Chemed reported Q3 earnings, with Roto-Rooter revenue up 7.5% but EBITDA down 2.5% due to higher costs. Commercial revenue grew 9% to $59.9M, while residential rose 5.2% to $158.8M. The company acquired California franchises for $62.5M, expecting $30M-$35M in 2027 revenue but less than $4M in EBITDA. Chemed repurchased 125,000 shares for $66M. Management expects 2026 EPS to meet or slightly exceed guidance.

finance.yahoo.com
$CHEMed

Chemed outlines 12- to 18-month integration timeline for $62.5M California Roto-Rooter franchise buyback while expecting 2026 EPS at or slightly above prior high end (NYSE:CHE)

Chemed (CHE) announced a 12- to 18-month integration timeline for its $62.5M California Roto-Rooter franchise buyback. CEO Kevin McNamara reported VITAS revenue grew 12.2% year-over-year, driven by ADC growth and cost containment. The company expects 2026 EPS to be at or slightly above the prior high end.

seekingalpha.com
$CHEHighAI 8/10

Chemed (CHE) Q3 2026 Earnings Call Transcript

Chemed (CHE) reported Q3 2026 earnings with total revenue up 10.6% and adjusted EPS up 28.1% YoY. VITAS saw 12.2% revenue growth, while Roto Rooter grew 7.5%. Roto Rooter's margins declined due to higher marketing costs and fuel expenses, but acquisitions are expected to drive long-term growth. The company has $229M in cash flow from operations, enabling strategic acquisitions and share repurchases.

finance.yahoo.com
$CHEHighAI 8/10

Why is Chemed stock surging today?

Chemed (CHE) stock rose 9.2% after Q3 earnings beat estimates, with adjusted EPS of $6.75 and revenue of $690.9M. VITAS hospice division showed strong growth. Jefferies upgraded the stock to Buy, raising its price target to $620. Bank of America also increased its target to $555. The stock hit a 52-week high.

investing.com